CISSPECT DESK-LAB

The world's first fully automated synthesis module

22 July 2020

The automated DESK-LAB process:

Ensures a high quality reproduction of each radiopharmaceutical batch

Reduces and simplifies the handling of radioactive material by the radiochemistry lab scientists

Automated GMP synthesis at your desk!

CISSPECT DESK-LAB represents a great leap forward for the development of radiopharmaceuticals and personalised drug discovery. Recently, we have developed the world’s first fully automated synthesis module, CISSPECT DESK-LAB, for the synthesis of Pt-195m cisplatin and other platinum compounds

The module has been designed for the production of GMP Pt-195m Cisplatin to facilitate a human pilot study. We have achieved this in close collaboration with our industrial partner FutureChemistry and renowned Dutch Academic Medical Centres.

CISSPECT CASE

process steps leading to results

DISSOLVE
DISSOLVE
Step 1
REDUCE
REDUCE
STEP 2
IODINATE
IODINATE
STEP 3
AMINATE
AMINATE
STEP 4
HYDROLYSE
HYDROLYSE
STEP 5
CHLORINATE
CHLORINATE
STEP 6
DISPENSE
DISPENSE
STEP 7

Results

Fully automated synthesis of Pt-195m cisplatin

For the GMP production of various Platinum compounds

Automated dispensing into patient doses

In addition to the Dhara synthesis according to Hoeschele et. al., Radiochimica Acta 1982

CISSPECT Future Chemistry

Partner: FutureChemistry

FutureChemistry Holding B.V. develops, builds and implements equipment and processes for manufacturing of chemicals with a high added value. With a focus in particular on two product groups: nanomaterials and radiopharmaceuticals.

  • Located at the Technology and Science Park of the Radboud University Nijmegen
  • Years of experience in flow chemistry

“A great leap forward for the development of radiopharmaceuticals and personalised drug discovery.“

CISSPECT = Pt-195m = radioactive cisplatin

The main draw backs of cisplatin chemotherapy treatment is kidney toxicity, as well as the low response rate in many cases, which cannot be predicted beforehand. Pt-195m cisplatin, or CISSPECT, is developed to enable quantification of the in vivo bio distribution of cisplatin, a standard chemotherapeutic agent. Pt-195m cisplatin may be able to select patients who will not respond to cisplatin chemotherapy, or those patients who will suffer from severe kidney toxicity due to cisplatin treatment.

CISSPECT PT 195M

CISSPECT® DESK-LAB - Automated GMP synthesis at your desk!

Human Pilot

The feasibility of SPECT imaging and quantification of Pt-195m in a preclinical setting has already been  shown (E.A. Aalbersberg et al., EJNMMI 2017 (44), 8, 1347 – 1354). As a next step, the feasibility in humans will be assessed. If successful, Pt-195m cisplatin contributes to optimising treatment outcome of chemo(radio)therapy and reducing toxicity in a personalised approach.

CISSPECT DESK LAB Proefstudie

Relevant produts

  • High specific activity
  • Reliable synthesis
  • For human use
Read more
  • No additional transport required from the reactor
  • Produced in parallel with molybdenum-99
  • Low enrichted uranium based (LEU)
Read more